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Lymphatic filariasis (LF) is an important  public health
problem in India not only due to morbid condition but
also due to social stigma, sexual incapacitation and
considerable economic loss. About 64% of global
population  who are at risk of LF infection are living
in southeast Asia region. It is estimated that 554.2
million people are at risk of LF infection in 243 dis-
tricts across 20 states and union territories in India1.
National Health Policy 2002 aims at elimination of
transmission and prevention of disability due to LF by
the year 2015. The most practical and feasible method
of controlling LF is rapid reduction of microfilarial
load in the community by annual mass drug adminis-
tration (MDA) of a single dose of Di-ethyl-
carbamazine (DEC). The World Health Organization
(WHO) has recently called on member of states to
identify the global elimination of LF as a public health
priority2. The global strategy to interrupt transmission
of LF is a single-dose, two-drug regimen to be used
by communities at risk with the goal of reaching 80%
coverage for 4–6 years3.
In India, 243 districts are identified as endemic dis-
tricts with 29 million people being parasite carriers
and 22 million with chronic disease.  Eight districts
are identified as endemic in Karnataka and Udupi dis-
trict is one of them. MDA of single dose DEC once
in a year was started in 2004 and four rounds of MDA
programme have been completed in the district.
Programme was based on a house-to-house approach
involving health department staff, anganwadi work-
ers, self-help groups, youth clubs, medical college
staff and students, etc. Prior to each round of drug
distribution, orientation and training sessions were
conducted in each PHC level for all the participants
(other than health and anganwadi staff participation
which was purely voluntary). Campaigns through
mass media (Television, Radio and Newspapers) and
banners, pamphlets, posters, jatha’s by schoolchildren
and miking were also conducted in most of the areas.
Door-to- door distribution of drugs was carried out
within three days of time. Factories, schools, institu-
tions and firms were covered  providing drugs at their
door steps. Drugs were distributed according to the
criteria prescribed by the Government of India. Pre-
dictions indicate that at least 90% consumption is
required to achieve the goal of elimination with five
rounds of annual DEC based MDA and 11 rounds are
required if the coverage is 60%4.
Current approaches to drug delivery are able to
achieve only 40–60% of coverage if MDA executed
by regular health services5. Therefore, the principal
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and researchers is to develop effective and sustainable
drug delivery strategies and also to find out the short-
comings of recently conducted programme with ref-
erence to coverage and compliance and to further
improve strategies for future rounds.
Therefore, a community-based cross-sectional  study
was conducted by faculty, trained medico-social
workers and health educators of the Department of
Community Medicine, Kasturba Medical College,
Manipal, Karnataka within a week following MDA
programme during September 2007 in Udupi district
of Karnataka state. The objective of the study was to
evaluate the coverage and compliance and to assess
the reasons for  non-coverage  and  non-compliance
of the programme and to examine the drug-related is-
sues such as side-effects, if any. A total of 13 clusters
were selected giving representation for urban and
rural areas of taluka. From each cluster five random
points were identified and at each point four houses
were randomly selected. There are 20 wards in Udupi
municipality area, taking feasibility into consideration
four wards were randomly selected, i.e. one out of
every five wards. In rural areas, nine villages were se-
lected—one village with Primary Health Centre
(PHC), six villages with sub-centres, and two villages
with no health  facilities. These clusters covered a
total of 260 households with a total population of
1145 persons of which 27 children were <2 yr. Ad-
hering to the  criteria of NVBDCP2  pregnant women,
children less than two years of age  and seriously ill
people were excluded from the study.  Therefore, for
compliance and coverage a total population of 1118
people was considered. A pre-tested questionnaire
was used to collect the data from the head of the
household or responsible member of the family.  Data
were analyzed using SPSS 11.0 software. Results
were summarized as percentages.
The socioeconomic and demographic characteristics
of the subjects are shown in Table 1. Majority of them
were Hindus (72.3%) and most of them (80.2%) were
in the age group of >15 yr. Around 15.9% (182) of
them were housewives. Around 44.8% were males
and 55.2% were females. Almost 92% of them were
Table 1. Socio-demographic characteristics of the
respondents (n = 1145)
Variables No. Percentage
Age
<23 months 27 2.3
2–4 yr 11 months 30 2.6
5–14 yr 11 months 171 14.9
>15 yr 917 80.2
Sex
Male 513 44.8
Female 632 55.2
Religion
Hindus 828 72.3
Muslims 163 14.2
Christians 154 13.5
Education
Illiterate 92 8.0
Primary 354 30.9
Secondary 349 30.5
Graduate 297 25.9
Pre-schooler 53 4.7
Occupation
Unskilled 79 6.9
Skilled 182 15.9
Professionals 187 16.3
Unemployed 268 23.4
Housewives 182 15.9
Students 165 14.4
Others 82 7.2
Table 2. Coverage and reasons for non-compliance of
drug administration
Variables No. Percentage
Coverage 821 73.4
Non-receipt of drugs 324 28.9
Swallowed drugs 703 62.8
Adequate dose received 775 94.4
Not eligible 15 12.7
Refused to consume  95 80.6
(felt not necessary/fear
of side-effects)
Failure to deliver medicine   8   6.7
literate. About 247 respondents (95%)  heard about
filariasis and 230 (88.5%) about the filariasis
programme.  Only 84.2% of the respondents were
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filariasis.  Table 2 shows that out of the total 1118 eli-
gible population 821 (73.4%) received the DEC tab-
lets, therefore, the coverage rate was 73.4%. Among
those who  received tablets,  it was observed that only
775 (94.4%) of the individuals received the adequate
dose and only 703 people actually consumed the tab-
lets. Hence,  compliance rate was 85.6%.  Compli-
ance refers to actual consumption of drug by the
community.
Around 324 (28.3%) did not receive the tablets. Fail-
ure to deliver the drug was reported by 224 (69.2%)
as common reason. In our study people did not per-
ceive filariasis as a serious  health problem and felt
they will not be affected by the disease as 118 (14.3%)
people  who received tablets did not consume the tab-
lets. The most common reason for not swallowing the
drug was the fear of side-effects 95 (80.6%)  while 8
(6.7%) did not consume for the reason of failure to
deliver the drugs. Side-effects were seen only among
8 (0.72%) of them.
Massive efforts have been taken by the National and
State governments along with WHO, towards elimi-
nation of LF in India as a public health problem. In a
country like India, annual MDA is an economic op-
tion6 and with improved strategies the existing health
care system is capable of operating the programme.
However, studies have shown that the main limitation
in this programme is a comparatively poor coverage
of drug distribution and consumption1,7–10. The rate
of coverage and compliance is the most crucial
factor in the success of MDA programme and this is
to a large extent dependant on the type of personnel
involved in drug distribution. About 86.6% of the re-
spondents in our study said that the person who dis-
tributed the drug was  known to them though 50.8%
of the drug distributors were government health
workers and only 16.7% medicine distributors ex-
plained about safety or the possible side-effects of
medicine. Therefore, there is an urgent need for more
effective drug delivery strategies.  In spite of high lit-
eracy rate among study population the 73.4% cover-
age observed by us was not satisfactory because
under the MDA the target was to ensure effective
coverage of 80% — a product of coverage as well as
compliance.
In the present study, 73 (31.7%) respondents came
to know about MDA from health personnel, 128
(55.6%) through media (TV, radio and miking) and
42 (18.2%) from NGOs. Mukhopadhyay et al11 in
their study found  that 77.8% respondents came to
know about MDA from health personnel and 20.8%
through media whereas NGO’s had very little in-
volvement (1.2%)11.
The study showed that there is a need to strengthen
the MDA programme planning and implementation
in terms of creating awareness through appropriate
media in the community. This can be achieved by ef-
ficient microplans, improved supervision emphasiz-
ing more strongly health work force training thereby
to improve the coverage and compliance through
community participation. As such, side-effects were
very few  and minor in our study which also need to
be addressed as they may constitute cause of future
non-compliance. Information about the Rapid Re-
sponse Team (RRT) must be widely publicized in
order to increase the faith of people which will indi-
rectly result in better compliance.
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